Potassium and its discontents: New insight, new treatments

Journal of the American Society of Nephrology

Volumn 27, Issue 4, 2016, Pages

  Ellison, David H ^a,b   Terker, Andrew S ^a   Gamba, Gerardo ^c  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b VETERANS AFFAIRS PORTLAND HEALTH CARE SYSTEM   (United States)

^c UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

LARGE CONDUCTANCE CALCIUM ACTIVATED POTASSIUM CHANNEL; PATIROMER; POLYSTYRENESULFONATE SODIUM; POTASSIUM; POTASSIUM ION; SODIUM CHLORIDE COTRANSPORTER; SODIUM ZIRCONIUM CYCLOSILICATE; SORBITOL;

CLINICAL TRIAL (TOPIC); GASTROINTESTINAL ABSORPTION; HUMAN; HYPERKALEMIA; NONHUMAN; PATHOGENESIS; POTASSIUM BLOOD LEVEL; POTASSIUM EXCRETION; POTASSIUM INTAKE; POTASSIUM METABOLISM; POTASSIUM TRANSPORT; POTASSIUM URINE LEVEL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; KIDNEY; METABOLISM;

HUMANS; HYPERKALEMIA; KIDNEY; POTASSIUM;

EID: 85006642589     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2015070751     Document Type: Review

References (92)

1. Sterns RH, Rojas M, Bernstein P, Chennupati S: Ion-exchange resins for the treatment of hyperkalemia: Are they safe and effective? J Am Soc Nephrol 21:733-735, 2010
2. Harel Z, Harel S, Shah PS, Wald R, Perl J, Bell CM: Gastrointestinal adverse events with sodium polystyrene sulfonate (Kayexalate) use: Asystematic review. Am J Med 126:264. e9-264.e24, 2013
3. Watson M, Abbott KC, Yuan CM: Damned if you do, damned if you don't: Potassium bindingresinsin hyperkalemia. Clin J Am Soc Nephrol 5:1723-1726, 2010
4. Cogswell ME, Zhang Z, Carriquiry AL, Gunn JP, Kuklina EV, Saydah SH, Yang Q, Moshfegh AJ: Sodium and potassium intakes among US adults: NHANES 2003-2008. Am J Clin Nutr 96:647-657, 2012
5. Mente A, O'Donnell MJ, Rangarajan S, McQueen MJ, Poirier P, Wielgosz A, Morrison H, Li W, Wang X, Di C, Mony P, Devanath A, Rosengren A, Oguz A, Zatonska K, Yusufali AH, Lopez-Jaramillo P, Avezum A, Ismail N, Lanas F, Puoane T, Diaz R, Kelishadi R, Iqbal R, Yusuf R, Chifamba J, Khatib R, Teo K, Yusuf S; PURE Investigators: Association of urinary sodium and potassium excretion with blood pressure. N Engl J Med 371:601-611, 2014
6. Weiner ID, Wingo CS: Hyperkalemia: A potential silent killer. J Am Soc Nephrol 9:1535-1543, 1998
7. Gumz ML, Rabinowitz L, Wingo CS: An integrated view of potassium homeostasis. N Engl J Med 373:60-72, 2015
8. Lee FN, Oh G, McDonough AA, Youn JH: Evidence for gut factor in K+ homeostasis. Am J Physiol Renal Physiol 293:F541-F547, 2007
9. Rabelink TJ, Koomans HA, Hené RJ, Dorhout Mees EJ: Early and late adjustment to potassium loading in humans. Kidney Int 38:942-947, 1990
10. Sennels HP, Jørgensen HL, Goetze JP, Fahrenkrug J: Rhythmic 24-hour variations of frequently used clinical biochemical parameters in healthy young males-the Bispebjerg study of diurnal variations. Scand J Clin Lab Invest 72:287-295, 2012
11. Moore Ede MC, Brennan MF, Ball MR: Circadian variation of intercompartmental potassium fluxes in man. J Appl Physiol 38:163-170, 1975
12. Wilmot B, Voruganti VS, Chang YP, Fu Y, Chen Z, Taylor HA, Wilson JG, Gipson T, Shah VO, Umans JG, Flessner MF, Hitzemann R, Shuldiner AR, Comuzzie AG, McWeeney S, Zager PG, Maccluer JW, Cole SA, Cohen DM: Heritability of serum sodium concentration: Evidence for sex- and ethnic-specific effects. Physiol Genomics 44:220-228, 2012
13. Welling PA: Regulation of renal potassium secretion: Molecular mechanisms. Semin Nephrol 33:215-228, 2013
14. Palmer BF: Regulation of potassium homeostasis. Clin J AmSoc Nephrol 10:1050-1060, 2015
15. Meneton P, Loffing J, Warnock DG: Sodium and potassium handling by the aldosteronesensitive distal nephron: The pivotal role of the distal and connecting tubule. Am J Physiol Renal Physiol 287:F593-F601, 2004
16. Gumz ML, Rabinowitz L: Role of circadian rhythms in potassium homeostasis. Semin Nephrol 33:229-236, 2013
17. Moore-Ede MC: Physiology of the circadian timing system: Predictive versus reactive homeostasis. Am J Physiol 250:R737-R752, 1986
18. Loffing J, Pietri L, Aregger F, Bloch-Faure M, Ziegler U, Meneton P, Rossier BC, Kaissling B: Differential subcellular localization of ENaC subunits in mouse kidneyin response to highand low-Na diets. Am J Physiol Renal Physiol 279:F252-F258, 2000
19. Velázquez H, Ellison DH, Wright FS: Chloridedependent potassium secretion in early and late renal distal tubules. Am J Physiol 253:F555-F562, 1987
20. Wade JB, Fang L, Coleman RA, Liu J, Grimm PR, Wang T, Welling PA: Differential regulation of ROMK (Kir1.1) in distal nephron segments by dietary potassium. Am J Physiol Renal Physiol 300:F1385-F1393, 2011
21. Frindt G, Palmer LG: Effects of dietary K on cell-surface expression of renal ion channels and transporters. Am J Physiol Renal Physiol 299:F890-F897, 2010
22. Wagner CA, Loffing-Cueni D, Yan Q, Schulz N, Fakitsas P, Carrel M, Wang T, Verrey F, Geibel JP, Giebisch G, Hebert SC, Loffing J: Mouse model of type II Bartter's syndrome. II. Altered expression of renal sodium- and water-transporting proteins. Am J Physiol Renal Physiol 294:F1373-F1380, 2008
23. Simon DB, Karet FE, Rodriguez-Soriano J, Hamdan JH, DiPietro A, Trachtman H, Sanjad SA, Lifton RP: Genetic heterogeneity of Bartter's syndrome revealed by mutations in the K+ channel, ROMK. Nat Genet 14:152-156, 1996
24. Sansom SC, Welling PA: Two channels for one job. Kidney Int 72:529-530, 2007
25. Cornelius RJ, Wen D, Li H, Yuan Y, Wang-France J, Warner PC, Sansom SC: Low Na, high K diet and the role of aldosterone in BK-mediated K excretion. PLoS One 10:e0115515, 2015
26. Simon DB, Nelson-Williams C, Bia MJ, Ellison D, Karet FE, Molina AM, Vaara I, Iwata F, Cushner HM, Koolen M, Gainza FJ, Gitleman HJ, Lifton RP: Gitelman's variant of Bartter's syndrome, inherited hypokalaemic alkalosis, is caused by mutations in the thiazidesensitive Na-Cl cotransporter. Nat Genet 12:24-30, 1996
27. Obermüller N, Bernstein P, Velázquez H, Reilly R, Moser D, Ellison DH, Bachmann S: Expression of the thiazide-sensitive Na-Cl cotransporter in rat and human kidney. Am J Physiol 269:F900-F910, 1995
28. Zhang C, Wang L, Zhang J, Su XT, Lin DH, Scholl UI, Giebisch G, Lifton RP, Wang WH: KCNJ10 determines the expression of the apical Na-Cl cotransporter (NCC) in the early distal convoluted tubule (DCT1). Proc Natl Acad Sci U S A 111:11864-11869, 2014
29. Wright FS: Increasing magnitudeofelectrical potential along the renal distal tubule. Am J Physiol 220:624-638, 1971
30. Wilson FH, Disse-Nicodème S, Choate KA, Ishikawa K, Nelson-Williams C, Desitter I, Gunel M, Milford DV, Lipkin GW, Achard JM, Feely MP, Dussol B, Berland Y, Unwin RJ, Mayan H, Simon DB, Farfel Z, Jeunemaitre X, Lifton RP: Human hypertension caused by mutations in WNK kinases. Science 293:1107-1112, 2001
31. Louis-Dit-Picard H, Barc J, Trujillano D, Miserey-Lenkei S, Bouatia-Naji N, Pylypenko O, Beaurain G, Bonnefond A, Sand O, Simian C, Vidal-Petiot E, Soukaseum C, Mandet C, Broux F, Chabre O, Delahousse M, Esnault V, Fiquet B, Houillier P, Bagnis CI, Koenig J, Konrad M, Landais P, Mourani C, Niaudet P, Probst V, Thauvin C, Unwin RJ, Soroka SD, Ehret G, Ossowski S, Caulfield M; International Consortium for Blood Pressure (ICBP) Bruneval P, Estivill X, Froguel P, Hadchouel J, Schott JJ, Jeunemaitre X: KLHL3 mutations cause familial hyperkalemic hypertension by impairing ion transport in the distal nephron. Nat Genet 44:456-460, 2012
32. Boyden LM, Choi M, Choate KA, Nelson-Williams CJ, Farhi A, Toka HR, Tikhonova IR, Bjornson R, Mane SM, Colussi G, Lebel M, Gordon RD, Semmekrot BA, Poujol A, Välimäki MJ, De Ferrari ME, Sanjad SA, Gutkin M, Karet FE, Tucci JR, Stockigt JR, Keppler-Noreuil KM, Porter CC, Anand SK, Whiteford ML, Davis ID, Dewar SB, Bettinelli A, Fadrowski JJ, Belsha CW, Hunley TE, Nelson RD, Trachtman H, Cole TR, Pinsk M, Bockenhauer D, Shenoy M, Vaidyanathan P, Foreman JW, Rasoulpour M, Thameem F, Al-Shahrouri HZ, Radhakrishnan J, Gharavi AG, Goilav B, Lifton RP: Mutations in kelchlike 3 and cullin 3 cause hypertension and electrolyte abnormalities. Nature 482:98-102, 2012
33. Lalioti MD, Zhang J, Volkman HM, Kahle KT, Hoffmann KE, Toka HR, Nelson-Williams C, Ellison DH, Flavell R, Booth CJ, Lu Y, Geller DS, Lifton RP: Wnk4 controls blood pressure and potassium homeostasis via regulation of mass and activity of the distal convoluted tubule. Nat Genet 38:1124-1132, 2006
34. Yang SS, Morimoto T, Rai T, Chiga M, Sohara E, Ohno M, Uchida K, Lin SH, Moriguchi T, Shibuya H, Kondo Y, Sasaki S, Uchida S: Molecular pathogenesis of pseudohypoaldosteronism type II: Generation and analysis of a Wnk4 (D561A/+) knockin mouse model. Cell Metab 5:331-344, 2007
35. Chávez-Canales M, Zhang C, Soukaseum C, Moreno E, Pacheco-Alvarez D, Vidal-Petiot E, Castañeda-Bueno M, Vázquez N, Rojas-Vega L, Meermeier NP, Rogers S, Jeunemaitre X, Yang C-L, Ellison DH, Gamba G, Hadchouel J: WNK-SPAK-NCC cascade revisited: WNK1 stimulates the activity of the Na-Cl cotransporter via SPAK, an effect antagonized by WNK4. Hypertension 64:1047-1053, 2014
36. Huang CL, Cheng CJ: A unifying mechanism for WNK kinase regulation of sodiumchloride cotransporter. Pflugers Arch 467:2235-2241, 2015
37. Thastrup JO, Rafiqi FH, Vitari AC, Pozo-Guisado E, Deak M, Mehellou Y, Alessi DR: SPAK/OSR1 regulate NKCC1 and WNK activity: Analysis of WNK isoform interactions and activation by T-loop trans-autophosphorylation. Biochem J 441:325-337, 2012
38. Yang C-L, Zhu X, Ellison DH: The thiazidesensitive Na-Cl cotransporter is regulated by a WNK kinase signaling complex. J Clin Invest 117:3403-3411, 2007
39. Piala AT, Moon TM, Akella R, He H, Cobb MH, Goldsmith EJ: Chloride sensing by WNK1 involves inhibition of autophosphorylation. Sci Signal 7: ra41, 2014
40. Terker AS, Zhang C, Erspamer KJ, Gamba G, Yang CL, Ellison DH: Unique chloridesensing properties of WNK4 permit the distal nephron to modulate potassium homeostasis [published online ahead of print September 30, 2015]. Kidney Int doi:10.1038/ki.2015.289
41. Terker AS, Zhang C, McCormick JA, Lazelle RA, Zhang C, Meermeier NP, Siler DA, Park HJ, Fu Y, Cohen DM, Weinstein AM, Wang WH, Yang CL, Ellison DH: Potassium modulates electrolyte balance and blood pressure through effects on distal cell voltage and chloride. Cell Metab 21:39-50, 2015
42. Bazua-Valenti S, Chavez-Canales M, Rojas-Vega L, Gonzalez-Rodriguez X, Vazquez N, Rodriguez-Gama A, Argaiz ER, Melo Z, Plata C, Ellison DH, Garcia-Valdes J, Hadchouel J, Gamba G: The effect of WNK4 on the Na+-Clcotransporter is modulated by intracellular chloride. J Am Soc Nephrol 26:1781-1786, 2015
43. Subramanya AR, Ellison DH: Distal convoluted tubule. Clin J Am Soc Nephrol 9:2147-2163, 2014
44. van der Lubbe N, Moes AD, Rosenbaek LL, Schoep S, Meima ME, Danser AH, Fenton RA, Zietse R, Hoorn EJ: K+-induced natriuresis is preservedduring Na+ depletionand accompanied by inhibition of the Na+-Clcotransporter. Am J Physiol Renal Physiol 305:F1177-F1188, 2013
45. Sorensen MV, Grossmann S, Roesinger M, Gresko N, Todkar AP, Barmettler G, Ziegler U, Odermatt A, Loffing-Cueni D, Loffing J: Rapid dephosphorylation of the renal sodium chloride cotransporter in response to oral potassium intake in mice. Kidney Int 83:811-824, 2013
46. Vitzthum H, Seniuk A, Schulte LH, Müller ML, Hetz H, Ehmke H: Functional coupling of renal K+ and Na+ handling causes high blood pressure in Na+ replete mice. J Physiol 592:1139-1157, 2014
47. Rengarajan S, Lee DH, Oh YT, Delpire E, Youn JH, McDonough AA: Increasing plasma [K+] by intravenous potassium infusion reduces NCC phosphorylation and drives kaliuresis and natriuresis. Am J Physiol Renal Physiol 306:F1059-F1068, 2014
48. Vallon V, Schroth J, Lang F, Kuhl D, Uchida S: Expression and phosphorylation of the Na+-Cl-cotransporter NCC in vivo is regulated by dietary salt, potassium, and SGK1. Am J Physiol Renal Physiol 297:F704-F712, 2009
49. Gomez-Sanchez CE: Channels and pumps in aldosterone-producing adenomas. J Clin Endocrinol Metab 99:1152-1156, 2014
50. Chiga M, Rai T, Yang SS, Ohta A, Takizawa T, Sasaki S, Uchida S: Dietary salt regulates the phosphorylation of OSR1/SPAK kinases and the sodium chloride cotransporter through aldosterone. Kidney Int 74:1403-1409, 2008
51. Sandberg MB, Riquier AD, Pihakaski-Maunsbach K, McDonough AA, Maunsbach AB: ANG II provokes acute traffickingofdistal tubule Na+-Cl (-) cotransporter to apical membrane. Am J Physiol Renal Physiol 293:F662-F669, 2007
52. van der Lubbe N, Lim CH, Fenton RA, Meima ME, Jan Danser AH, Zietse R, Hoorn EJ: Angiotensin II induces phosphorylation of the thiazide-sensitive sodium chloride cotransporter independent of aldosterone. Kidney Int 79:66-76, 2011
53. San-Cristobal P, Pacheco-Alvarez D, Richardson C, Ring AM, Vazquez N, Rafiqi FH, Chari D, Kahle KT, Leng Q, Bobadilla NA, Hebert SC, Alessi DR, Lifton RP, Gamba G: Angiotensin II signaling increases activity of the renal Na-Cl cotransporter through a WNK4-SPAK-dependent pathway. Proc Natl Acad Sci U S A 106:4384-4389, 2009
54. Castañeda-Bueno M, Cervantes-Pérez LG, Vázquez N, Uribe N, Kantesaria S, Morla L, Bobadilla NA, Doucet A, Alessi DR, Gamba G: Activation of the renal Na+:Cl-cotransporter by angiotensin II is a WNK4-dependent process. Proc Natl Acad Sci U S A 109:7929-7934, 2012
55. Shibata S, Zhang J, Puthumana J, Stone KL, Lifton RP: Kelch-like 3 and Cullin 3 regulate electrolyte homeostasis via ubiquitination and degradation of WNK4. Proc Natl Acad Sci U S A 110:7838-7843, 2013
56. Mamenko M, Zaika O, Ilatovskaya DV, StaruschenkoA, Pochynyuk O: Angiotensin II increases activity of the epithelial Na+ channel (ENaC) in distal nephron additively to aldosterone. J Biol Chem 287:660-671, 2012
57. Sun P, Yue P, Wang WH: Angiotensin II stimulates epithelial sodium channels in the cortical collecting duct of the rat kidney. Am J Physiol Renal Physiol 302:F679-F687, 2012
58. Stegbauer J, Gurley SB, Sparks MA, Woznowski M, Kohan DE, Yan M, Lehrich RW, Coffman TM: AT1 receptors in the collecting duct directly modulate the concentration of urine. J Am Soc Nephrol 22:2237-2246, 2011
59. Wei Y, Zavilowitz B, Satlin LM, Wang WH: Angiotensin II inhibits the ROMK-like small conductance K channel in renal cortical collecting duct during dietary potassium restriction. J Biol Chem 282:6455-6462, 2007
60. Yue P, Sun P, Lin DH, Pan C, Xing W, Wang W: Angiotensin II diminishes the effect of SGK1 on the WNK4-mediated inhibition of ROMK1 channels. Kidney Int 79:423-431, 2011
61. Todkar A, Picard N, Loffing-Cueni D, Sorensen MV, Mihailova M, Nesterov V, Makhanova N, Korbmacher C, Wagner CA, Loffing J: Mechanisms of renal control of potassium homeostasis in complete aldosterone deficiency. J Am Soc Nephrol 26:425-438, 2015
62. Shibata S, Rinehart J, Zhang J, Moeckel G, Castañeda-Bueno M, Stiegler AL, Boggon TJ, Gamba G, Lifton RP: Mineralocorticoid receptor phosphorylation regulates ligand binding and renal response to volume depletion and hyperkalemia. Cell Metab 18:660-671, 2013
63. Leviel F, Hübner CA, Houillier P, Morla L, El Moghrabi S, Brideau G, Hassan H, Parker MD, Kurth I, Kougioumtzes A, Sinning A, Pech V, Riemondy KA, Miller RL, Hummler E, Shull GE, Aronson PS, Doucet A, Wall SM, Chambrey R, Eladari D: The Na+-dependent chloride-bicarbonate exchanger SLC4A8 mediates an electroneutral Na+ reabsorption process in the renal cortical collecting ducts of mice. J Clin Invest 120:1627-1635, 2010
64. Keith NM, Binger MW: Diuretic action of potassium salts. JAMA 105:1584-1591, 1935
65. Aburto NJ, Hanson S, Gutierrez H, Hooper L, Elliott P, Cappuccio FP: Effect of increased potassium intake on cardiovascular risk factors and disease: Systematic review and meta-analyses. BMJ 346:f1378, 2013
66. O'Donnell M, Mente A, Rangarajan S, McQueen MJ, Wang X, Liu L, Yan H, Lee SF, Mony P, Devanath A, Rosengren A, Lopez-Jaramillo P, Diaz R, Avezum A, Lanas F, Yusoff K, Iqbal R, Ilow R, Mohammadifard N, Gulec S, Yusufali AH, Kruger L, Yusuf R, Chifamba J, Kabali C, Dagenais G, Lear SA, Teo K, Yusuf S; PURE Investigators: Urinary sodium and potassium excretion, mortality, and cardiovascular events. N Engl J Med 371:612-623, 2014
67. Krishna GG, Kapoor SC: Potassium depletion exacerbates essential hypertension. Ann Intern Med 115:77-83, 1991
68. Krishna GG, Kapoor SC: Potassium supplementation ameliorates mineralocorticoidinduced sodium retention. Kidney Int 43:1097-1103, 1993
69. Adrogué HJ, Madias NE: Sodium surfeit and potassium deficit: Keys to the pathogenesis of hypertension. J Am Soc Hypertens 8:203-213, 2014
70. Montasser ME, Shimmin LC, Gu D, Chen J, Gu C, Kelly TN, Jaquish CE, Rice T, Rao DC, Cao J, Chen J, Liu DP, Whelton P, He J, Hixson JE: Blood pressure response to potassium supplementation is associated with genetic variation in endothelin 1 and interactions with E selectin in rural Chinese. J Hypertens 28:748-755, 2010
71. Zhang Z, Cogswell ME, Gillespie C, Fang J, Loustalot F, Dai S, Carriquiry AL, Kuklina EV, Hong Y, Merritt R, Yang Q: Association between usual sodium and potassium intake and blood pressure and hypertension among U. S. adults: NHANES 2005-2010. PLoS One 8:e75289, 2013
72. He FJ, Marciniak M, Carney C, Markandu ND, Anand V, Fraser WD, Dalton RN, Kaski JC, MacGregor GA: Effects of potassium chloride and potassium bicarbonate on endothelial function, cardiovascular risk factors, and bone turnover in mild hypertensives. Hypertension 55:681-688, 2010
73. Adrogué HJ, Madias NE: Sodium and potassium in the pathogenesis of hypertension. N Engl J Med 356:1966-1978, 2007
74. Einhorn LM, Zhan M, Hsu VD, Walker LD, Moen MF, Seliger SL, Weir MR, Fink JC: The frequency of hyperkalemia and its significance in chronic kidney disease. Arch Intern Med 169:1156-1162, 2009
75. Vardeny O, Claggett B, Anand I, Rossignol P, Desai AS, Zannad F, Pitt B, Solomon SD; Randomized Aldactone Evaluation Study (RALES) Investigators: Incidence, predictors, and outcomes related to hypo- and hyperkalemia in patients with severe heart failure treated with a mineralocorticoid receptor antagonist. Circ Heart Fail 7:573-579, 2014
76. Desai AS: Hyperkalemia in patients with heart failure: Incidence, prevalence, and management. Curr Heart Fail Rep 6:272-280, 2009
77. Lazich I, Bakris GL: Prediction and management of hyperkalemia across the spectrum of chronic kidney disease. Semin Nephrol 34:333-339, 2014
78. Palmer BF: Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system. N Engl J Med 351:585-592, 2004
79. Einhorn LM, Zhan M, Hsu VD, Walker LD, Moen MF, Seliger SL, Weir MR, Fink JC: The frequency of hyperkalemia and its significance in chronic kidney disease. Arch Intern Med 169(12):1156-1162, 2009
80. Sarafidis PA, Blacklock R, Wood E, Rumjon A, Simmonds S, Fletcher-Rogers J, Ariyanayagam R, Al-Yassin A, Sharpe C, Vinen K: Prevalence and factors associated with hyperkalemia in predialysis patients followed in a low-clearance clinic. Clin J Am Soc Nephrol 7:1234-1241, 2012
81. Kovesdy CP: Management of hyperkalemia: An update for the internist [published online ahead of print June 18, 2015]. Am J Med doi: 10.1016/j.amjmed.2015.05.040
82. Watson MA, Baker TP, Nguyen A, Sebastianelli ME, Stewart HL, Oliver DK, Abbott KC, Yuan CM: Association of prescription of oral sodium polystyrene sulfonate with sorbitol in an inpatient setting with colonic necrosis: A retrospective cohort study. Am J Kidney Dis 60:409-416, 2012
83. Stavros F, Yang A, Leon A, Nuttall M, Rasmussen HS: Characterization of structure and function of ZS-9, a K+ selective ion trap. PLoS One 9:e114686, 2014
84. Packham DK, Rasmussen HS, Lavin PT, El-Shahawy MA, Roger SD, Block G, Qunibi W, Pergola P, Singh B: Sodium zirconium cyclosilicate in hyperkalemia. N Engl J Med 372:222-231, 2015
85. Kosiborod M, Rasmussen HS, Lavin P, Qunibi WY, Spinowitz B, Packham D, Roger SD, Yang A, Lerma E, Singh B: Effect of sodium zirconium cyclosilicate on potassium lowering for 28 days among outpatients with hyperkalemia: The HARMONIZE randomized clinical trial. JAMA 312:2223-2233, 2014
86. Kosiborod M, Peacock WF, Packham DK: Sodium zirconium cyclosilicate for urgent therapy of severe hyperkalemia. N Engl J Med 372:1577-1578, 2015
87. Weir MR, Bakris GL, Bushinsky DA, Mayo MR, Garza D, Stasiv Y, Wittes J, Christ-Schmidt H, Berman L, Pitt B; OPAL-HK Investigators: Patiromer inpatients with kidney disease and hyperkalemia receiving RAAS inhibitors. N Engl J Med 372:211-221, 2015
88. Bakris GL, Pitt B, Weir MR, Freeman MW, Mayo MR, Garza D, Stasiv Y, Zawadzki R, Berman L, Bushinsky DA; AMETHYST-DN Investigators: Effect of patiromer on serum potassium level in patients with hyperkalemia and diabetic kidney disease: The AMETHYST-DN Randomized Clinical Trial. JAMA 314:151-161, 2015
89. Agus MS, Agus ZS: Cardiovascular actions of magnesium. Crit Care Clin 17:175-186, 2001
90. Winkelmayer WC: Treatment of hyperkalemia: From "hyperK+" strikeouttohome run? JAMA 314:129-130, 2015
91. Ingelfinger JR: A new era for the treatment of hyperkalemia? N Engl J Med 372:275-277, 2015
92. Gruy-Kapral C, Emmett M, Santa Ana CA, Porter JL, Fordtran JS, Fine KD: Effect of single dose resin-cathartic therapy on serum potassium concentration in patients with end-stage renal disease. J Am Soc Nephrol 9:1924-1930, 1998